Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA, EMA Seek Biosimilar Pathway Convergence

This article was originally published in The Pink Sheet Daily

Executive Summary

The deputy director of FDA's Europe Office discusses the collaboration between FDA and the European Medicines Agency; the agencies are looking for ways to develop a common biosimilar development program.

You may also be interested in...



Biosimilars: FDA, EMA Developing Common Data Package Guidance

Guidance is “emerging” that will allow sponsors to use data from products not licensed in their respective regions in applications.

Sandoz Biosimilar Strategy For Etanercept: Start Small, But Test Globally

Sandoz has begun a global Phase III trial with its biosimilar version of Amgen's Enbrel (etanercept), targeting psoriasis rather than the more lucrative indication for rheumatoid arthritis, with the aim of winning quicker regulatory approval which can be built on as it gains insights testing the medicine.

Sandoz Biosimilar Strategy For Etanercept: Start Small, But Test Globally

Sandoz has begun a global Phase III trial with its biosimilar version of Amgen's Enbrel (etanercept), targeting psoriasis rather than the more lucrative indication for rheumatoid arthritis, with the aim of winning quicker regulatory approval which can be built on as it gains insights testing the medicine.

Related Content

Topics

UsernamePublicRestriction

Register

PS072822

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel